Aikium Wins Prestigious 2025 Nebius AI Discovery Award for Drug Discovery Innovation
Amsterdam June 18th 2025
We are proud to announce that Aikium has been honored with the 2025 Nebius AI Discovery Award in the Drug Discovery category, recognizing our groundbreaking work in targeting "undruggable" proteins using our proprietary Yotta-ML² platform. This award, presented on June 18, 2025, in Amsterdam, highlights Aikium’s leadership in leveraging deep learning to revolutionize protein therapeutics, particularly in areas previously considered inaccessible by traditional methods.
Selected from a competitive pool of 257 global applicants by a distinguished panel of 19 independent judges from leading biotech, pharmaceutical, research, and venture capital organizations, Aikium stood out for its validated AI-driven approach and clear path to market impact. Our platform’s success in proof-of-concept studies on difficult targets has already led to partnerships with four organizations, including three top cancer hospitals, underscoring the clinical and therapeutic potential of our technology.
The Nebius AI Discovery Awards, backed by Nebius (NASDAQ: NBIS), offer $100,000 in GPU cloud credits to each winner to accelerate their AI innovations. This recognition not only affirms Aikium’s pioneering role in drug discovery but also provides critical resources to further advance our mission to transform treatment options for complex diseases.
We extend our gratitude to Nebius and the judging panel for this honor and remain committed to pushing the boundaries of AI-driven drug discovery to bring new hope to patients worldwide.
